Show results for
Refine by
Clinical Study Equipment & Supplies
2 equipment items found
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
FIN-211 is an orally administered, Enriched Consortia product candidate designed to address both the gastrointestinal (GI) and behavioral symptoms of ASD. ASD is a behaviorally defined condition characterized by difficulties with interpersonal interaction, communication, and repetitive or restrictive patterns of behavior and activities. A subset of individuals with ASD experience significant GI ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the treatment of chronic HBV. Chronic HBV infection occurs when the initial immune response fails to clear the virus, and may result in inflammation of hepatocytes, and complications including cirrhosis, liver ...